Population pharmacokinetics of nebulized arformoterol in subjects with COPD

G. Maier, J. Kharidia, J. Hanrahan, R. Hsu, D. Jaworowicz, B. Cirincione, J. Owen, T. Grasela (Marlborough, Buffalo, United States Of America)

Source: Annual Congress 2006 - Update on treatment of COPD II
Session: Update on treatment of COPD II
Session type: Thematic Poster Session
Number: 2499
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Maier, J. Kharidia, J. Hanrahan, R. Hsu, D. Jaworowicz, B. Cirincione, J. Owen, T. Grasela (Marlborough, Buffalo, United States Of America). Population pharmacokinetics of nebulized arformoterol in subjects with COPD. Eur Respir J 2006; 28: Suppl. 50, 2499

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The pharmacokinetics of inhaled NVA237 in COPD patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013



Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

Exposure-response relationship for nebulized arformoterol in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006

Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD: preliminary observations
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019


A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 213s
Year: 2006

The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Long-term safety of inhaled formoterol in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009

48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011